Clinical trial
A Phase 2 "Window of Opportunity" Trial of Targeted Therapy With Erdafitinib in Patients With Recurrent FGFR3-Altered Non-Muscle Invasive Bladder Cancer
NCT04917809 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 "Window of Opportunity" Trial of Targeted Therapy With Erdafitinib in Patients With Recurrent FGFR3-Altered Non-Muscle Invasive Bladder Cancer
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- February 17, 2022
- Completion date
- August 31, 2027
- Enrollment
- 20 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
bladder cancer, fgfr3 gene mutation, recurrent bladder cancer